Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Omid Hamid

Showing results (71-80 of 188) with videos related to

Pageof 19
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2019
Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in <i>BRAF</i>-Mutant MelanomaAntoni Ribas, Adil Daud, Anna C Pavlick, et al.
Journal for Immunotherapy of Cancer|July 24, 2021
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding studyRachel E Sanborn, Omid Hamid, Elisabeth Ge de Vries, et al.
Journal for Immunotherapy of Cancer|March 22, 2019
Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanomaGeoffrey T Gibney, Omid Hamid, Jose Lutzky, et al.
Investigational New Drugs|February 24, 2021
LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trialAfshin Dowlati, R Donald Harvey, Richard D Carvajal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2025
First-in-Human Phase 1/2 Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid TumorsOmid Hamid, Dana B Cardin, F Stephen Hodi, et al.
Journal of Translational Medicine|April 8, 2021
The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020Paolo A Ascierto, Michael B Atkins, Alexander M Eggermont, et al.
Journal for Immunotherapy of Cancer|May 4, 2023
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trialJason A Chesney, Igor Puzanov, Frances A Collichio, et al.
The Lancet. Oncology|March 30, 2012
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trialKim Margolin, Marc S Ernstoff, Omid Hamid, et al.
Cancer|March 29, 2014
A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanomaOmid Hamid, Robert Ilaria, Claus Garbe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2016
Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia StudyDavid F McDermott, Jeffrey A Sosman, Mario Sznol, et al.
Pageof 19

Showing results (71-80 of 188) with videos related to

Sort By:
Pageof 19
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2019
Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in <i>BRAF</i>-Mutant MelanomaAntoni Ribas, Adil Daud, Anna C Pavlick, et al.
Journal for Immunotherapy of Cancer|July 24, 2021
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding studyRachel E Sanborn, Omid Hamid, Elisabeth Ge de Vries, et al.
Journal for Immunotherapy of Cancer|March 22, 2019
Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanomaGeoffrey T Gibney, Omid Hamid, Jose Lutzky, et al.
Investigational New Drugs|February 24, 2021
LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trialAfshin Dowlati, R Donald Harvey, Richard D Carvajal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2025
First-in-Human Phase 1/2 Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid TumorsOmid Hamid, Dana B Cardin, F Stephen Hodi, et al.
Journal of Translational Medicine|April 8, 2021
The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020Paolo A Ascierto, Michael B Atkins, Alexander M Eggermont, et al.
Journal for Immunotherapy of Cancer|May 4, 2023
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trialJason A Chesney, Igor Puzanov, Frances A Collichio, et al.
The Lancet. Oncology|March 30, 2012
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trialKim Margolin, Marc S Ernstoff, Omid Hamid, et al.
Cancer|March 29, 2014
A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanomaOmid Hamid, Robert Ilaria, Claus Garbe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2016
Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia StudyDavid F McDermott, Jeffrey A Sosman, Mario Sznol, et al.
Pageof 19